Tirzepatide Maintains Dominance At the same time, tirzepatide, while still dominating the market with 55 per cent of total GLP-1 sales, also saw monthly sales rise by 6 per cent to Rs 121 crore (Rs 1.21 billion) in April 2026, from Rs 114 crore (Rs 1.14 billion) in March
These medications can vary in side effects, how theyre taken, and overall cost
E., Puskas, B
It works by neutralizing free radicals in the body, which helps prevent cell and tissue damage, leading to improvements in skin texture, color tone, and overall radiance
The GLP-1 Bridge program will cover three drugs, Foundayo, Wegovy and Zepbound, and be available to people who have Medicare Part D, an optional extra coverage to lower the cost of prescriptions
Effects of Oral Butyrate Supplementation on Inflammatory Potential of Circulating Peripheral Blood Mononuclear Cells in Healthy and Obese Males